News

Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.

Mpox virus evades the innate immune system by interfering with antiviral pathways signaling and interferon responses, increasing replication, and complicating outbreak management, especially in non-endemic regions.

These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.

Recent study establishes that the generic glecaprevir/pibrentasvir is bioequivalent to the brand name version, offering the same therapeutic benefits.

Despite the differences in clinical presentation, MRSA strains remain susceptible to several key antibiotics, emphasizing the importance of targeted treatment and postoperative education in preventing MRSA infections.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

NOWDiagnostics' represents a new option for early syphilis detection and aligns with ongoing efforts to improve STI screening.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.

Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

The vaccine, Jynneos, manufactured by Bavarian Nordic, is being shipped to Africa to address the ongoing mpox outbreak.

Results reveal that the antiviral did not significantly improve lesion resolution in mpox patients compared to placebo, but it did report a lower mortality rate among participants than that seen in the broader DRC cases.

This is the very first such declaration by the Africa CDC since its inception in 2017.

Jeffery Silber MD, highlights VE303's consistent formulation as an advantage over traditional fecal transplants and discusses how the trial's patient-centric approach aims to improve outcomes and reduce healthcare-associated infections.

Individual antibiotics are ranked by risk for C difficile infection in an analysis of both randomized controlled trials and national adverse event reports.

In part 2 of this interview with Deborah Birx, MD, she highlights that ActivePure Technology provides a continuous decontamination solution that operates independently of manual intervention to reduce HAIs.

Peggy Lillis Foundation CEO Christian Lillis talks about how he became involved in advocacy around C diff and his motivation in helping to bring a bill to Congress to make the healthcare-associated infection a nationally notifiable infectious disease and condition.

Addressing this threat requires the development of effective vaccines and therapeutics specifically targeting evolving H5N1 viruses.

Penicillin continues to be an important therapy for treating syphilis. Here is a review of the literature in comparing one of the first antibiotics to non-penicillin treatments for non-neurological syphilis.

Study highlights that many long-term symptoms may result from ongoing inflammation rather than persistent viral presence.

Pfizer's Phase 3 MONeT trial shows that Abrysvo is safe and effective in producing strong immune responses against RSV in immunocompromised adults.

With the ongoing war between Israel and Hamas, The World Health Organization reported a public health update. Officials are concerned about what is happening inside the Gaza Strip particularly around a variety of diseases and health conditions including hepatitis A, skin infections, and even polio.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Baby formula manufacturer, Perrigo, issued a voluntary recall due to high levels of vitamin D that were above the maximum level permitted.

Part 1, Deborah Birx, MD explains photohydrolysis technology provides continuous, automated disinfection of air and surfaces effective in controlling MRSA and improving infection control practices in healthcare settings.